Neuroleptic malignant syndrome and preexisting brain damage
Abstract
A case of neuroleptic malignant syndrome (NMS) is described in a congenitally brain-damaged deaf patient. The literature suggests that NMS in patients with organic brain syndrome is induced by a reduction of marginal stores of dopamine in the hypothalamus and basal ganglia resulting from dopamine-blocking activity of neuroleptics, even at conventionally low doses. Brain-damaged patients should be recognized as being at higher risk of developing NMS.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).